Arrowhead Pharmaceuticals (ARWR) News
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARWR news summary
We found 12 recent headlines mentioning Arrowhead Pharmaceuticals (ARWR): 0 in the past week and 9 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. ARWR is making an outsized move today, down 5.22% at $41.37, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Arrowhead Pharmaceuticals, Inc. Reports Fiscal 2026 Results and Announces $400 million Refinancing", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Arrowhead Pharmaceuticals headlines
- Arrowhead Pharmaceuticals, Inc. Reports Fiscal 2026 Results and Announces $400 million RefinancingArrowhead Pharmaceuticals, Inc. reported its financial results for the fiscal year ended September 30, 2026, with revenue of $ 450,817 thousand compared to $ 829,448 thousand in the prior fiscal…Nasdaq
- Arrowhead (ARWR) Q4 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqARWR, WSO.B
- Arrowhead Pharmaceuticals GAAP EPS of -$5.11 misses by $1.51, revenue of $450.82M misses by $13.32MSeeking Alpha
- Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End ResultsPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting…Business Wire
- Arrowhead Pharmaceuticals FY 2026 Earnings PreviewSeeking Alpha
- Arrowhead Pharmaceuticals Becomes Oversold (ARWR)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq
- Arrowhead Pharmaceuticals options signal 8.1% move on earningsInvesting.com
- Arrowhead Pharmaceuticals, Inc. Refinances Senior Secured Term Loans with $400.0 million Credit FacilityOn November 2, 2026, Arrowhead Pharmaceuticals, Inc. and its subsidiary, Arrowhead Madison Inc., refinanced its senior secured term loans by entering into an Amended and Restated Financing Agreement…Nasdaq
- Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End ResultsPASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its…Business Wire
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) - This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.NasdaqABBV, ANL, ARWR, AZN
- Arrowhead Reports Positive Phase 1/2a Data For Alzheimer's Candidate ARO-MAPT(RTTNews) - Arrowhead Pharmaceuticals, Inc. (ARWR) announced positive interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic…NasdaqARWR, ET
- Why is Arrowhead Pharmaceuticals stock surging today?Investing.com